Edgewise Therapeutics (EWTX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Edgewise Therapeutics (EWTX)
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Key Insights
Critical company metrics and information
Share Price
$32.38Market Cap
$3.07 BillionTotal Outstanding Shares
94.69 Million SharesTotal Employees
108Dividend
No dividendIPO Date
March 26, 2021SIC Description
Pharmaceutical PreparationsHomepage
https://www.edgewisetx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities | $-108.90 Million |
Net Cash Flow, Continuing | $11.85 Million |
Net Cash Flow From Investing Activities, Continuing | $-178.59 Million |
Net Cash Flow From Investing Activities | $-178.59 Million |
Net Cash Flow From Financing Activities | $299.35 Million |
Net Cash Flow | $11.85 Million |
Net Cash Flow From Operating Activities, Continuing | $-108.90 Million |
Net Cash Flow From Financing Activities, Continuing | $299.35 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Diluted Earnings Per Share | $1.49 |
Income/Loss From Continuing Operations After Tax | $-124.29 Million |
Basic Average Shares | $184.71 Million |
Diluted Average Shares | $184.71 Million |
Net Income/Loss Attributable To Parent | $-124.29 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Other Operating Expenses | $28.87 Million |
Net Income/Loss | $-124.29 Million |
Operating Income/Loss | $-147.15 Million |
Research and Development | $118.28 Million |
Income/Loss From Continuing Operations Before Tax | $-124.29 Million |
Revenues | $0.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss Available To Common Stockholders, Basic | $-124.29 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Operating Expenses | $147.15 Million |
Basic Earnings Per Share | $1.49 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Current Liabilities | $7.12 Million |
Liabilities And Equity | $511.28 Million |
Wages | $6.18 Million |
Fixed Assets | $9.97 Million |
Equity | $488.88 Million |
Liabilities | $22.41 Million |
Noncurrent Liabilities | $3.45 Million |
Accounts Payable | $5.65 Million |
Equity Attributable To Parent | $488.88 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Other Non-current Assets | $1.88 Million |
Assets | $511.28 Million |
Current Liabilities | $18.96 Million |
Current Assets | $499.44 Million |
Noncurrent Assets | $11.85 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.